Joan Massague

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-? pathway and reveal microRNA regulation of TGFBR2
    Nikolaus Schultz
    Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Silence 2:3. 2011
  2. ncbi G1 cell-cycle control and cancer
    Joan Massague
    Cancer Biology and Genetics Program, and Howard Hughes Medical Institute, Box 116, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York 10021, USA
    Nature 432:298-306. 2004
  3. ncbi TGF-beta signal transduction
    J Massague
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Annu Rev Biochem 67:753-91. 1998
  4. ncbi The logic of TGFbeta signaling
    Joan Massague
    Cancer Biology and Genetics Program, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, P O Box 116, 1275 York Avenue, New York, NY 10021, USA
    FEBS Lett 580:2811-20. 2006
  5. ncbi How cells read TGF-beta signals
    J Massague
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, Box 116, 1275 York Avenue, New York, New York 10021, USA
    Nat Rev Mol Cell Biol 1:169-78. 2000
  6. ncbi Genome-wide impact of the BRG1 SWI/SNF chromatin remodeler on the transforming growth factor beta transcriptional program
    Qiaoran Xi
    Cancer Biology and Genetics Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Biol Chem 283:1146-55. 2008
  7. ncbi TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4
    David Padua
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cell 133:66-77. 2008
  8. ncbi Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling
    Sheng Gao
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mol Cell 36:457-68. 2009
  9. ncbi Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation
    Joan Seoane
    Cancer Biology and Genetics Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 1300 York Avenue, New York, NY 1002, USA
    Cell 117:211-23. 2004
  10. ncbi Genes that mediate breast cancer metastasis to the brain
    Paula D Bos
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 459:1005-9. 2009

Research Grants

Collaborators

Detail Information

Publications51

  1. ncbi Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-? pathway and reveal microRNA regulation of TGFBR2
    Nikolaus Schultz
    Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Silence 2:3. 2011
    ..abstract:..
  2. ncbi G1 cell-cycle control and cancer
    Joan Massague
    Cancer Biology and Genetics Program, and Howard Hughes Medical Institute, Box 116, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York 10021, USA
    Nature 432:298-306. 2004
    ....
  3. ncbi TGF-beta signal transduction
    J Massague
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Annu Rev Biochem 67:753-91. 1998
    ..Mutations in these pathways are the cause of various forms of human cancer and developmental disorders...
  4. ncbi The logic of TGFbeta signaling
    Joan Massague
    Cancer Biology and Genetics Program, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, P O Box 116, 1275 York Avenue, New York, NY 10021, USA
    FEBS Lett 580:2811-20. 2006
    ..The deconstruction of one of these responses - the cell cycle arrest response - into its elemental molecular parts has shed light into the mechanisms used by tumors to evade surveillance and cause metastasis...
  5. ncbi How cells read TGF-beta signals
    J Massague
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, Box 116, 1275 York Avenue, New York, New York 10021, USA
    Nat Rev Mol Cell Biol 1:169-78. 2000
    ..What are the networks of cell-specific molecules that mould the TGF-beta response to each cell's needs?..
  6. ncbi Genome-wide impact of the BRG1 SWI/SNF chromatin remodeler on the transforming growth factor beta transcriptional program
    Qiaoran Xi
    Cancer Biology and Genetics Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Biol Chem 283:1146-55. 2008
    ..Our results provide a genome-wide scope of the participation of BRG1 in TGFbeta action and suggest a widespread yet differential involvement of BRG1 SWI/SNF remodeler in the transcriptional response of many genes to this cytokine...
  7. ncbi TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4
    David Padua
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cell 133:66-77. 2008
    ....
  8. ncbi Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling
    Sheng Gao
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mol Cell 36:457-68. 2009
    ..Previously identified as a regulator of renal sodium channels, Nedd4L is shown here to play a broader role as a general modulator of Smad turnover during TGF-beta signal transduction...
  9. ncbi Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation
    Joan Seoane
    Cancer Biology and Genetics Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 1300 York Avenue, New York, NY 1002, USA
    Cell 117:211-23. 2004
    ..We suggest that the activity of this network confers resistance to TGF-beta-mediated cytostasis during the development of the telencephalic neuroepithelium and in glioblastoma brain tumor cells...
  10. ncbi Genes that mediate breast cancer metastasis to the brain
    Paula D Bos
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 459:1005-9. 2009
    ..This co-option of a brain sialyltransferase highlights the role of cell-surface glycosylation in organ-specific metastatic interactions...
  11. ncbi Balancing BMP signaling through integrated inputs into the Smad1 linker
    Gopal Sapkota
    Cancer Biology and Genetics Program, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mol Cell 25:441-54. 2007
    ..The interplay between linker phosphorylation, Smurf-dependent ubiquitination, and nucleoporin exclusion enables regulation of BMP action by diverse signals and biological contexts...
  12. ncbi Distinct domain utilization by Smad3 and Smad4 for nucleoporin interaction and nuclear import
    Lan Xu
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Biol Chem 278:42569-77. 2003
    ....
  13. ncbi WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis
    Don X Nguyen
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cell 138:51-62. 2009
    ..For a video summary of this article, see the PaperFlick file available with the online Supplemental Data...
  14. ncbi Endogenous human microRNAs that suppress breast cancer metastasis
    Sohail F Tavazoie
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 451:147-52. 2008
    ..miR-335 and miR-126 are thus identified as metastasis suppressor microRNAs in human breast cancer...
  15. ncbi Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage
    Joan Seoane
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nature 419:729-34. 2002
    ..By inhibiting p21(Cip1) expression Myc favours the initiation of apoptosis, thereby influencing the outcome of a p53 response in favour of cell death...
  16. ncbi A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells
    Yibin Kang
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Cell 11:915-26. 2003
    ..As a common target of TGFbeta/Smad signals and stress signals via p38 kinase, ATF3 additionally serves to channel synergy between these pathways in the response of epithelial cells to stress and injury...
  17. ncbi Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways
    Claudio Alarcon
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell 139:757-69. 2009
    ..Thus, nuclear CDK8/9 drive a cycle of Smad utilization and disposal that is an integral part of canonical BMP and TGF-beta pathways...
  18. ncbi Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway
    Yibin Kang
    Cancer Biology and Genetics Program and Howard Hughes Medical Institute, Molecular Cytology Laboratory, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Proc Natl Acad Sci U S A 102:13909-14. 2005
    ..Our findings provide functional evidence for a switch of the Smad pathway, from tumor-suppressor to prometastatic, in the development of breast cancer bone metastasis...
  19. ncbi Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway
    Wei He
    Cancer Biology and Genetics Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell 125:929-41. 2006
    ..Thus, Smad2/3-TIF1gamma and Smad2/3-Smad4 function as complementary effector arms in the control of hematopoietic cell fate by the TGFbeta/Smad pathway...
  20. ncbi Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways
    Gopal Sapkota
    Cancer Biology and Genetics Program, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Biol Chem 281:40412-9. 2006
    ....
  21. ncbi C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells
    Roger R Gomis
    Cancer Biology and Genetics Program, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Cell 10:203-14. 2006
    ..We suggest that C/EBPbeta plays a key role in the coordination of TGFbeta cytostatic gene responses, and its malfunction may trigger evasion of these responses in breast cancer...
  22. ncbi E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression
    Chang Rung Chen
    Cell Biology Program, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell 110:19-32. 2002
    ..Smad proteins therefore mediate transcriptional activation or repression depending on their associated partners...
  23. ncbi Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs
    Thordur Oskarsson
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Med 17:867-74. 2011
    ..These findings link TNC to pathways that support the fitness of metastasis-initiating breast cancer cells and highlight the relevance of TNC as an extracellular matrix component of the metastatic niche...
  24. ncbi Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-beta-mediated epithelial cell growth suppression
    Peter M Siegel
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021
    J Biol Chem 278:35444-50. 2003
    ..These results argue that induction of Mad expression and Id2 down-regulation are important events during the TGF-beta cytostatic program in epithelial cells...
  25. ncbi A multigenic program mediating breast cancer metastasis to bone
    Yibin Kang
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Cell 3:537-49. 2003
    ....
  26. ncbi Multimodality imaging of TGFbeta signaling in breast cancer metastases
    Inna Serganova
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    FASEB J 23:2662-72. 2009
    ....
  27. ncbi Tumor self-seeding by circulating cancer cells
    Mi Young Kim
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell 139:1315-26. 2009
    ..Tumor self-seeding could explain the relationships between anaplasia, tumor size, vascularity and prognosis, and local recurrence seeded by disseminated cells following ostensibly complete tumor excision...
  28. ncbi Genes that mediate breast cancer metastasis to lung
    Andy J Minn
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 436:518-24. 2005
    ..Others contribute to aggressive growth selectively in the lung. Many encode extracellular proteins and are of previously unknown relevance to cancer metastasis...
  29. ncbi Mediators of vascular remodelling co-opted for sequential steps in lung metastasis
    Gaorav P Gupta
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 446:765-70. 2007
    ..These findings reveal how aggressive primary tumorigenic functions can be mechanistically coupled to greater lung metastatic potential, and how such biological activities may be therapeutically targeted with specific drug combinations...
  30. ncbi Latent bone metastasis in breast cancer tied to Src-dependent survival signals
    Xiang H F Zhang
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Cell 16:67-78. 2009
    ..Breast cancer cells that lodge in the bone marrow succumb in this environment when deprived of Src activity...
  31. ncbi Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGFbeta signaling complexes in the cytoplasm and nucleus
    Lan Xu
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mol Cell 10:271-82. 2002
    ..Thus, by directly contacting the nuclear pore complex, Smad2 undergoes constant shuttling, providing a dynamic pool that is competitively drawn by cytoplasmic and nuclear signal transduction partners...
  32. ncbi Diverted total synthesis leads to the generation of promising cell-migration inhibitors for treatment of tumor metastasis: in vivo and mechanistic studies on the migrastatin core ether analog
    Thordur Oskarsson
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA
    J Am Chem Soc 132:3224-8. 2010
    ..Both in vivo and in vitro studies indicate that ME exhibits a concentration-dependent inhibitory effect on migration of breast cancer cells...
  33. ncbi A poised chromatin platform for TGF-? access to master regulators
    Qiaoran Xi
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cell 147:1511-24. 2011
    ..In turn, Smad4 increases K18 acetylation to augment TRIM33-Smad2/3 binding. Thus, nodal effectors use the H3K9me3 mark as a platform to switch master regulators of stem cell differentiation from the poised to the active state...
  34. ncbi TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
    Dori A Thomas
    Cancer Biology and Genetics Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Cell 8:369-80. 2005
    ..We suggest that TGF-beta suppresses CTL function in vivo through an anticytotoxic program of transcriptional repression...
  35. ncbi Genetic determinants of cancer metastasis
    Don X Nguyen
    Cancer Biology and Genetics Program, and Howard Hughes Medical Institute, Box 116, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York 10021, USA
    Nat Rev Genet 8:341-52. 2007
    ..With knowledge cemented in decades of research into tumour-initiating events, current experimental and conceptual models are beginning to address the genetic basis for cancer colonization of distant organs...
  36. ncbi MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer
    Kim J Png
    Laboratory of Systems Cancer Biology, Rockefeller University, New York, NY 10065, USA
    Genes Dev 25:226-31. 2011
    ..We furthermore identify miR-335 as a robust inhibitor of tumor reinitiation. We thus implicate the miR-335 locus on 7q32.2 as the first selective metastasis suppressor and tumor initiation suppressor locus in human breast cancer...
  37. ncbi ID genes mediate tumor reinitiation during breast cancer lung metastasis
    Gaorav P Gupta
    Cancer Biology and Genetics Program, Molecular Cytology Core Facility, Human Oncology and Pathogenesis Program, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 104:19506-11. 2007
    ..These results shed light on the proliferative mechanisms that initiate metastatic colonization, and they implicate Id1 and Id3 as mediators of this malignant function in the TN subgroup of breast cancers...
  38. ncbi Roles of TGFbeta in metastasis
    David Padua
    Cancer Biology and Genetics Program, and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 116, New York, NY 10065, USA
    Cell Res 19:89-102. 2009
    ..The development of TGFbeta inhibitors for clinical use will require a deeper understanding of TGFbeta signaling, its consequences, and the contexts in which it acts...
  39. ncbi Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis
    Peter M Siegel
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:8430-5. 2003
    ....
  40. ncbi Smad transcription factors
    Joan Massague
    Cancer Biology and Genetics Program, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Genes Dev 19:2783-810. 2005
    ..Our growing understanding of TGFbeta signaling through the Smad pathway provides general principles for how animal cells translate complex inputs into concrete behavior...
  41. ncbi Breast cancer methylomes establish an epigenomic foundation for metastasis
    Fang Fang
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Sci Transl Med 3:75ra25. 2011
    ..These findings significantly enhance our understanding of breast cancer oncogenesis and aid the development of new prognostic biomarkers for this common malignancy...
  42. ncbi Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs
    Qing Chen
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Cell 20:538-49. 2011
    ..Thus, newly disseminated cancer cells expressing VCAM-1 can thrive in leukocyte-rich microenvironments through juxtacrine activation of a VCAM-1-Ezrin-PI3K/Akt survival pathway...
  43. ncbi Clinical implications of cancer self-seeding
    Elizabeth Comen
    Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill College of Medicine of Cornell University, New York, NY 10021, USA
    Nat Rev Clin Oncol 8:369-77. 2011
    ..Indeed, reframing our understanding of metastasis within the self-seeding model offers new opportunities for prevention and cure of metastatic cancer...
  44. ncbi Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer
    Anna Rodina
    Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Chem Biol 3:498-507. 2007
    ..These results provide important evidence for a transformation-specific interplay between chaperones in regulating apoptosis in malignant cells...
  45. ncbi Modeling metastasis in the mouse
    Paula D Bos
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Curr Opin Pharmacol 10:571-7. 2010
    ..By integrating the information obtained with these complementary approaches the field is currently obtaining an unprecedented level of understanding of the biology, molecular basis, and therapeutic vulnerabilities of metastasis...
  46. ncbi Metastasis: from dissemination to organ-specific colonization
    Don X Nguyen
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nat Rev Cancer 9:274-84. 2009
    ....
  47. ncbi A very private TGF-beta receptor embrace
    Joan Massague
    Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mol Cell 29:149-50. 2008
    ..In this issue of Molecular Cell, Groppe et al. (2008) describe the crystal structure of a six-element TGF-beta:receptor complex, addressing long-standing questions about the restrictive nature of this vital receptor interaction...
  48. ncbi TGFbeta in Cancer
    Joan Massague
    Cancer Biology and Genetics Program, and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cell 134:215-30. 2008
    ..The mechanistic basis and clinical relevance of TGFbeta's role in cancer is becoming increasingly clear, paving the way for a better understanding of the complexity and therapeutic potential of this pathway...
  49. ncbi HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPß isoforms
    Anna Arnal-Estapé
    Oncology Programme, Institute for Research in Biomedicine, Barcelona, Spain
    Cancer Res 70:9927-36. 2010
    ..Our findings reveal a novel mechanism through which HER2 silences tumor suppression in a concerted manner, contributing to the potency of this oncogene in breast cancer...
  50. ncbi Integration of Smad and MAPK pathways: a link and a linker revisited
    Joan Massague
    Cancer Biology and Genetics Program, and Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Genes Dev 17:2993-7. 2003

Research Grants2

  1. Transforming Growth Factor-Beta Signal Transduction
    Joan Massague; Fiscal Year: 2007
    ..Through this proposed work, we wish to furnish the field with a better understanding of the role of the TGFb/Smad pathway in physiology and a better ability to manage this pathway in tumor progression, metastasis and other disorders. ..